On January 14, 2008, FDA approved Tysabri (natalizumab) for certain patients with moderate-to-severe Crohn’s disease, a chronic inflammatory condition of the digestive tract. Here are facts about the symptoms and treatments for this condition.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
